Loading
Amelia Zellander

Amelia Zellander

CEO, BioLattice Ophthalmics, Inc.
United States
Amelia Zellander, PhD is a bioengineer with extensive industry experience in medical device and pharmaceutical R&D. During her PhD studies at the University of Illinois at Chicago, she created a cornea replacement technology that was submitted to the United States Patent and Trade Office for a patent filing. After completing her PhD, Dr. Zellander developed cell therapies and medical devices in R&D roles at Janssen R&D (a Johnson & Johnson company) and Imvax. In 2017, while working full-time as a scientist at a pharmaceutical company, Dr. Zellander initiated a cornea research project at Lehigh University. For the $42,700 Pennsylvania Department of Health award granted to Lehigh in 2021, Dr. Zellander was a co-investigator and key contributor to the completion of the grant application. In 2023, Dr. Zellander’s fundraising efforts yielded over $300,000 in funding. She won the $80,000 1st place prize in The Enterprise Center’s “Most Diverse Tech Hub” pitch competition in 2023. Also in 2023, BioLattice was awarded $274,000 in National Science Foundation SBIR Phase 1 funding. $25,000 in private investment was received in 2024. Fundraising and R&D efforts continue to support the company’s next pivotal milestone: demonstration of engineered cornea function in an animal model.
Sessions

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS